Stockreport

CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia...

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of HEMGENIX ® (etranacogene dezaparvovec). HEMGENIX is the fir [Read more]